Sign Up to like & get recommendations! 0
Published in 2018 at "Current Colorectal Cancer Reports"
DOI: 10.1007/s11888-018-0407-8
Abstract: Purpose of ReviewEarly prediction of response to chemoradiotherapy in locally advanced rectal cancer has the potential to minimize surgical intervention in patients with complete response, while allowing non-responding patients to explore more aggressive treatments. Functional… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Journal of the American Academy of Child and Adolescent Psychiatry"
DOI: 10.1016/j.jaac.2022.03.033
Abstract: INTRODUCTION Emotional dysregulation and irritability are common in individuals with autism spectrum disorder (ASD). We conducted the first meta-analysis assessing the efficacy of a broad range of pharmacological interventions for emotional dysregulation and irritability in… read more here.
Sign Up to like & get recommendations! 1
Published in 2018 at "Expert Opinion on Investigational Drugs"
DOI: 10.1080/13543784.2018.1416091
Abstract: ABSTRACT Introduction: Inhibitors against the PD-1/PD-L1 pathway are revolutionizing the treatment and management of malignancies. Areas covered: We summarize our current understanding of the function of PD-1, its role in immune evasion, the clinical data… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Psychosomatic Medicine"
DOI: 10.1097/psy.0000000000001078
Abstract: ABSTRACT Objective There is growing evidence that open-label placebo (OLP) may be an efficacious treatment of chronic and functional conditions. However, patient-level predictors of response to OLP have not been clearly identified. The aim of… read more here.
Sign Up to like & get recommendations! 0
Published in 2018 at "European Journal of Neurology"
DOI: 10.1111/ene.13523
Abstract: OnabotulinumtoxinA is a treatment specifically approved for the prophylaxis of chronic migraine in adults. The aim of this study was to assess the effectiveness of OnabotulinumtoxinA in chronic migraine after 1 year of treatment in… read more here.
Sign Up to like & get recommendations! 0
Published in 2020 at "European journal of endocrinology"
DOI: 10.1530/eje-20-0767
Abstract: BACKGROUND The treatment of acromegaly resistant to first generation somatostatin receptor ligands (SRLs) is often difficult. Pegvisomant and Pasireotide LAR are mostly used in these subset of patients, as second line therapies. Choice of the… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "International heart journal"
DOI: 10.1536/ihj.21-497
Abstract: The AMBITION study (NCT01178073) provided the first long-term clinical evidence for initial combination therapy with ambrisentan and tadalafil in patients with pulmonary arterial hypertension (PAH). Nevertheless, predictors of treatment response were not assessed.To identify predictors… read more here.
Sign Up to like & get recommendations! 0
Published in 2021 at "Biomedicines"
DOI: 10.3390/biomedicines9030304
Abstract: Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with limited treatment options in the advanced stages. Immunotherapy offers hope for altering the orthodox management of cancer, and its role in advanced ACC has been investigated… read more here.
Sign Up to like & get recommendations! 0
Published in 2017 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms18061182
Abstract: Despite advances in diagnosis and new treatments such as targeted therapies, breast cancer (BC) is still the most prevalent tumor in women worldwide and the leading cause of death. The principal obstacle for successful BC… read more here.